Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 in moderate to severe hidradenitis suppurativa
NCT05093855Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BDB-001 in hidradenitis suppurativa (HS), sponsored by Staidson Biopharmaceutical. Started Aug 2021; status: completed.
02
Drugs
BDB-001
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05093855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093855.